Allogeneic human histocompatibility leukocyte antigen (HLA)-matched tumor cell lines that have been made immunogenic by the transfer of genes encoding for costimulatory molecules such as CD80 are considered to be potential vaccines for the induction of systemic immune reactions in cancer patients. We used a human HLA-A2.1 ϩ CD80-transfected breast carcinoma cell line (KS-CD80) and investigated in vitro the efficiency at which antigen (Ag)-specific responses were induced following the stimulation of allogeneic HLA-A2.1-matched T lymphocytes. The influenza matrix protein M1 was used as a model Ag. It was either endogenously expressed or exogenously loaded as a peptide (matrix protein), and the frequency of the generated specific T cells was determined. The expression of CD80 in KS cells was required for an effective activation and expansion of Ag-specific T cells. This response was augmented following the pretreatment of KS-CD80 cells with interferon-␥ and tumor necrosis factor-␣. Interleukin-4 (IL-4), IL-7, and IL-12 further increased T-cell expansion. IL-7 was best at supporting the generation of T cells with Ag specificity. This investigation demonstrates that allogeneic CD80 ϩ tumor cells can induce Ag-specific, HLA-restricted T lymphocytes at a high frequency. Our study supports the use of allogeneic cell lines for the induction of specific T-cell responses in tumor patients.
T umor cells express specific antigens (Ags) that can be recognized by T lymphocytes and may serve as targets for immunologic tumor destruction. 1 Therefore, tumor cells can be used as an Ag reservoir for the activation of tumor-specific T lymphocytes. However, most tumor cells are only weakly immunogenic per se and do not effectively induce immune responses against their Ags. This is frequently due to their lack of costimulatory molecules at the cell surface. 2 Therefore, several strategies have been developed to improve the immunogenicity of tumor cells, including the transfer of genes that encode cytokines or costimulatory molecules. 3 Costimulatory molecules such as CD80 (B7-1) or CD86 (B7-2) deliver secondary signals via interaction with their respective receptors (i.e., CD28). Such signals are necessary for T-cell proliferation, cytokine release, and differentiation into cytolytic effector cells. 4 Contact with Ags alone induces T-cell unresponsiveness and anergy. 5, 6 Unlike professional Ag-presenting cells (APCs), epithelial tumor cells do not express CD80 or CD86. The transfer of genes encoding such costimulatory molecules into tumor cells is aimed at conferring the Ag-presenting capacity of tumor cells and at preventing anergy. 7, 8 Murine tumor models have shown that CD80 or CD86 gene-transduced tumor cells induce specific T cell-mediated immune responses and offer protection against a second challenge with unmodified tumors. 9 -13 The use of CD80-/CD86-transduced immunogenic tumor cells as vaccines represents a strategy for the induction of systemic antitumor immune responses in cancer patients as well. Two approaches have been developed for vaccinating purposes using ex vivo gene-modified human tumor cells: (a) the use of autologous tumor cells obtained during tumor resection and (b) the use of allogeneic human histocompatibility leukocyte Ag (HLA)-matched established tumor cell lines. The rationale behind using allogeneic HLA-matched tumor cell lines is the induction of T-cell responses against Ags presented by matched HLA alleles that are common to both the vaccine and the patient's tumor. The fact that certain HLA alleles are frequently expressed (i.e., HLA-A2.1: 30 -40% in the Caucasian population) supports the use of HLA-matched vaccines. Such an allogeneic approach has an advantage in that a rather large group of patients can be treated with an identical well-characterized tumor cell inoculum.
The present study was aimed at determining, at a quantitative level, the ability of allogeneic HLAmatched CD80 transfected tumor cells to induce peptide Ag-specific T lymphocytes. We used the human HLA-A2.1 ϩ breast carcinoma cell line (KS) that had been transfected previously to stably express CD80 and that, in contrast with unmodified cells, induced the proliferation of resting allogeneic T lymphocytes.
14 Moreover, CD80-transfected KS cells promoted the in vitro expansion of CD8 ϩ T-cell lines with cytolytic activity against unmodified tumor cells. The stimulatory potential of CD80-transfected KS cells was further augmented by pretreating the cells with interferon-␥ (IFN-␥) plus tumor necrosis factor-␣ (TNF-␣). Both cytokines augmented major histocompatibility complex (MHC) class I expression and induced CD54 and MHC class II molecules.
14 Here, the ability of the CD80-expressing KS variant to activate Ag-specific T cells in allogeneic situations was quantitated using a known viral T-cell Ag.
MATERIALS AND METHODS

Cells
The human breast carcinoma cell line KS was cultured in Dulbecco's modified Eagle's medium (Life Technologies, Eggenstein, Germany) supplemented with 10% fetal calf serum (Serva, Heidelberg, Germany), 4 mM L-glutamine (Life Technologies), and 1% penicillin/streptomycin (Life Technologies). The CD80-transfected KS variant KS-CD80 was described previously.
14 Culture medium for KS-CD80 was supplemented with 0.5 mg/mL G418 (Life Technologies). Cytokine-treated tumor cells were obtained by incubating the cells overnight with 250 U/mL IFN-␥ (Boehringer Mannheim, Mannheim, Germany) and 25 ng/mL TNF-␣ (Boehringer Mannheim) in culture medium. Peripheral blood mononuclear cells (PBMCs) were prepared from the peripheral blood of healthy donors by density-gradient centrifugation using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). T lymphocytes were subsequently prepared by adherence on plastic dishes followed by rosetting with sheep erythrocytes. Expression of the HLA-A2 allele was determined by immunofluorescence using the monoclonal antibody (mAb) BB7.2 (American Type Culture Collection (ATCC), Manassas, Va). The A0201* subtype was confirmed using specific polymerase chain reaction primers in the Department of Immunohematology and Bloodbank (University Hospital, Leiden, The Netherlands). Lymphocytes were cultured in RPMI 1640 (Life Technologies) supplemented with 10% fetal calf serum, 4 mM L-glutamine, and 1% penicillin/ streptomycin. 15 KS-CD80 cells (5 ϫ 10 6 ) were plated in a 15-cm culture dish. After cultivation for 3 days, the cells were transfected using 25 g of pUHD-10.1-M1, 2.5 g of pX343 (providing hygromycin resistance), and 50 L of Lipofectin (Life Technologies) according to the manufacturer's protocol. Stable transfectants were selected using 100 g/mL hygromycin (Merck, Darmstadt, Germany) for 3 weeks and were subsequently pooled and maintained in culture medium containing 50 g/mL hygromycin.
Matrix protein (MP) transfection
Generation of MP-specific T cells
A total of 1.5 ϫ 10 6 T lymphocytes were cocultured in 24-well plates with 1.5 ϫ 10 5 MP-pulsed, ␥-irradiated (200 Gy) tumor cells or 1.5 ϫ 10 6 MP-pulsed, ␥-irradiated (30 Gy) PBMCs. For MP-pulsing, 1-5 ϫ 10 6 cells/mL were incubated with 3 g/mL of influenza MP 57-68 (KGILGFVFTLTV) for 1 hour at 37°C, 5% CO 2 , and washed twice to remove free peptide. Natural human interleukin-2 (IL-2) (40 U/mL) (provided by Biotest, Dreieich, Germany) was added on day 3. T cells were restimulated in weekly intervals under identical conditions. The following cytokines were also added: recombinant IL-4 (1 ng/mL) and IL-7 (1 ng/mL) starting on day 3 of the first stimulation and recombinant IL-12 (0.1 ng/mL; R&D Systems, Wiesbaden, Germany) starting on day 0 of the second stimulation.
Flow cytometry analysis
Indirect immunofluorescence was performed as described previously. 15 The following mAbs were used: OKT3 (anti-CD3, 10 g/mL, ATCC), 19Thy5D7 (anti-CD4, ascites 1/1000, provided by Dr. E. Reinherz, Dana Faber Cancer Institute, Boston, Mass), 7PT3F9 (anti-CD8, ascites 1/1000, from E. Reinherz), anti-CD16 (ascites, 1/1000, provided by Dr. R. E. Schmidt, Medizinische Hochschule, Hannover, Germany), anti-CD56 (Biermann), and BB7.2 (anti-HLA-A2, supernatant, undiluted, ATCC). Fluorescein isothiocyanate-labeled anti-mouse immunoglobulin (Dako, Hamburg, Germany) diluted 1/40 in culture medium was used as a secondary mAb. The secondary mAb alone was used as negative control, and 5000 cells were analyzed on a Coulter Profile 1 flow cytometer (Coulter Electronics, Hialeah, Fla) with logarithmic amplification (3 log scale) through a viable cell gate as determined by forward and side scatter.
Enzyme-linked immunospot (ELISPOT) assay
Multiscreen 96-well nitrocellulose plates (Millipore, Bedford, Mass) were coated with 50 L of mouse anti-human IFN-␥ mAb (2 g/mL in phosphate-buffered saline (PBS); Genzyme, Rüsselsheim, Germany) for 2 hours at room temperature (RT) and blocked with 200 L of PBS/1% bovine serum albumin (BSA) (Sigma, Deisenhofen, Germany) for 1 hour at RT. T cells were cultured at different cell numbers in coated 96-well Multiscreen plates for 18 hours at 37°C, 5% CO 2 , together with 3.5 ϫ 10 4 unpulsed or MP-pulsed T2 cells or with 1 ϫ 10 4 KS-CD80 tumor cells. T2 is an Ag-processing-defective cell line that does not express any MHC molecules, with the exception of low levels of HLA-A0201*. 16 The plates were washed four times with PBS/1% BSA/0.05% Tween 20 (Sigma). PBS/BSA/Tween was then used for the additional washing and incubation steps. Wells were incubated with 100 L of rabbit anti-human IFN-␥ polyclonal antibody (1/250, Genzyme) for 2 hours at RT and washed four times; next, 100 L of peroxidase-conjugated goat anti-rabbit immunoglobulin G (heavy and light) polyclonal antibody (1/500, Southern Bio-technology Associates, Birmingham, Ala) was added. After 1 hour of incubation at RT, the supernatant was discarded, the wells were washed four times with PBS/BSA, and 50 L of substrate (12.5 mg/mL of 3-amino-9-ethylcarbazol (Sigma) in dimethylformamide diluted 1/45 in 4.5 mL of sodium acetate buffer at pH 5.0 plus 2 L 30% H 2 O 2 filtrated with a 0.2-m filter) was added. The supernatant was discarded after 7-15 minutes, the wells were air-dried overnight, and colored spots were counted in a stereomicroscope. The number of MPspecific T cells represents the number of spots obtained following incubation with MP-pulsed T2 cells, subtracting all background spots obtained following incubation with T2 cells alone. The number of reactive cells per 10,000 cells was calculated by linear regression out of the number of specific T lymphocytes in 30,000, 15,000, 7500, and 3750 cells, and in 10,000, 3000, 1000, and 300 cells, respectively.
Cytotoxicity assay
The cytolytic activity of the T cells was tested in a standardized 51 Cr release assay using 10 3 target cells/well. T cells were incubated for 4 hours with labeled T2 or K562 cells, and influenza MP 57-68 was added at a final concentration of 1 g/mL. Specific cytotoxicity was calculated according to the following formula: ([experimental cpm Ϫ spontaneous cpm]/ [maximal cpm Ϫ spontaneous cpm]) ϫ 100.
RESULTS
The influenza A virus MP-derived synthetic peptide MP 57-68 was used in conjunction with HLA-A2.1 ϩ autologous PBMCs, allogeneic PBMCs, or allogeneic tumor cells, respectively, to induce MP 57-68 peptide-specific T lymphocytes. Figure 1 shows that autologous PBMCs from an HLA-A2.1 ϩ donor generated specific T cells at a frequency of 1 per 118 and 1 per 34 on days 14 and 28, respectively, as determined by IFN-␥ release in an ELISPOT assay. Note that in the case of this particular donor, no Ag-specific IFN-␥-secreting T cells were detectable prior to any in vitro stimulation (data not shown). When allogeneic HLA-A2.1-matched PBMCs from an unrelated donor were used as APCs, the frequency of specific T cells was initially lower compared with the autologous stimulation (day 14) but reached comparable levels on day 28 (Fig 1) . This finding indicates that peptide-Ag-specific T cells were at least as effectively generated by allogeneic as by autologous APCs. Importantly, because the total number of cells in allogeneic cultures was approximately seven times higher than in the autologous situation, the absolute number of Ag-specific T lymphocytes was 7-fold larger in the allogeneic situation.
An HLA-A2.1 ϩ breast carcinoma cell line transfected with the CD80 gene (KS-CD80) and pretreated with IFN-␥ plus TNF-␣ was then tested for its capacity to induce MP 57-68 -specific T cells from two representative allogeneic HLA-A2.1 ϩ donors. Figure 2 shows that peptide-specific T cells were indeed generated by the cytokine-pretreated MP 57-68 -pulsed allogeneic KS-CD80 tumor variant. Allostimulation alone in the absence of MP 57-68 did not result in the generation of specific T lymphocytes. Notably, the potential of the tumor cell variant to induce specific T cells proved as effective as autologous PBMCs in single cases (compare donor 2 in Fig 2) . However, in other cases, such as donor 1 (Fig 2) , the frequency of the specific T cells generated by the tumor cell variant was one-thirteenth the frequency obtained following autologous PBMC stimulation. The precursor frequency prior to stimulation (donor 1, 0/150,000; donor 2, 12/150,000) and the time required to obtain specific T cells may have contributed to this difference between individual donors.
We transfected a plasmid containing cDNA of the influenza A virus MP M1 into KS-CD80 breast carcinoma cells to test T-cell activation following endogenous Ag processing and presentation. Figure 3 demonstrates ϩ KS cells that were unpulsed (OE) or pulsed with MP 57-68 (F). T cells were restimulated weekly, and the frequency of the MP-specific T cells was determined on days 21 (donor 1) and 7 (donor 2), respectively, by ELISPOT using MP 57-68 -pulsed and unpulsed T2 cells as stimulator cells.
that an uncloned, stable M1 transfectant stimulated MP-specific T cells of an allogeneic HLA-A2.1 ϩ donor. Moreover, the frequency of specific T cells was similar to experiments using peptide-pulsed KS-CD80 cells or pulsed autologous PBMCs as stimulators. The T-cell response was enhanced after loading M1-transfected KS-CD80 cells with MP peptide, probably indicating that not all HLA-A2.1 molecules were occupied by the endogenously processed peptide. Table 1 demonstrates the contribution of IFN-␥ and TNF-␣ treatment of allogeneic KS breast cancer cells and of CD80 expression to the generation of specific T lymphocytes. Although a few MP 57-68 -specific T cells seemed to be activated by untreated or IFN-␥/TNF-␣-pretreated parental tumor cells, they could not be expanded in vitro. In contrast, CD80 expression alone did result in the activation of specific T cells and in their expansion. However, best results were obtained following stimulation with IFN-␥/TNF-␣-pretreated CD80-transfected tumor cells, yielding a substantial number of specific T cells on day 28.
Having verified the ability of allogeneic KS-CD80 breast cancer cells to activate specific T cells against the M1 peptide, we investigated the influence of lymphokines to further improve this response. As shown in Table 2 , T cells stimulated in the presence of IL-2 showed an activity against an Ag peptide that was nearly identical with the activity observed against the allogeneic stimulator tumor cell in the absence of Ag peptide (225 vs. 276 in 10,000 cells, Table 2 ). This observation supports a high proportion of Ag-specific T cells in comparison with allo-or natural killer (NK)-reactive cells. The combination of IL-2 with IL-4, IL-7, or IL-12 increased T-cell growth by ϳ2-fold. The addition of IL-12 favored the activation of CD8 ϩ T cells; however, it reduced the fraction of Ag-specific T cells and increased allo-and NK-related reactivity. A combination with IL-7 yielded a high proportion of Ag-specific cells but decreased the fraction of CD8 ϩ T cells, whereas a combination with IL-4 increased the fraction of CD8 ϩ T cells compared with conditions with IL-2 alone.
Because a high frequency of peptide-specific T cells was generated under the above conditions (Յ1/45), we also determined the cytolytic activity of these T cells. MP 57-68 -specific cytolytic activity could be demonstrated in all cultures (Fig 4) . As noted previously (Table 2) , IL-12 generated the highest amount of NK activity, as detected by K562 lysis. We demonstrated the potential of a human breast carcinoma cell line transfected with the CD80 gene to induce Ag-specific T-lymphocyte responses in an alloge- [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ). This observation demonstrates efficient endogenous Ag processing and presentation by this tumor cell line. Furthermore, this finding shows that defined viral Ag can serve as surrogate tumor Ag, and that peptide loading can serve as a meaningful approach to compare the potential of different tumor cell variants to induce the expansion of Ag-specific T cells. The fact that specific T-cell responses were efficiently generated following stimulation with allogeneic APCs demonstrates that the additional activation of allo-and NK-reactive cells did not interfere with specificity. Thus, the number of MP 57-68 -specific T cells was comparable with the number of allo-and NK-reactive cells, stressing the efficient activation of HLA-A2.1-restricted, Ag-specific T cells. Moreover, due to improved growth conditions, the total number of specific T cells was higher following allogeneic versus autologous stimulations. This may be explained by the activation of Th cells (i.e., by class II alloantigen) and by the release of helper cytokines.
The transfer of genes encoding allogeneic MHC molecules, also known as xenogenization, was used in the past to improve the immunogenicity of animal tumor cells. Expression of alloantigen, achieved either by ex vivo or in situ gene transfer, resulted in tumor rejection and in the induction of specific immune responses against unmodified tumor cells. 17, 18 Recently, Knight et al 19 presented a murine vaccination model that clearly demonstrated the superiority of a cell-based allogeneic melanoma vaccine. In that study, in contrast with autologous tumor cells, a single application of an MHCunrelated melanoma induced protection against subsequent challenge with the autologous tumor. 19 It seems likely that allogeneic MHC molecules act as a nonspecific adjuvant, inducing an immunologic environment accompanied by inflammatory cytokine secretion, and thus enabling host APCs to infiltrate and present shared tumor Ag after uptake and processing. Whether this leads to the activation of tumor-specific cytotoxic T lymphocytes (CTLs) relevant for the elimination of already existent micrometastases remains to be assessed in adjuvant therapeutical settings. In this regard, clinical studies using in situ gene transfer to express allogeneic HLA-B7 in melanomas have been initiated. 20 Other groups previously showed the induction of tumor-specific T-cell responses by HLA-A2-matched allogeneic melanoma cells. 21, 22 This response was, to a large extent, directed to the melanocyte differentiation Ag MART-1 and was induced even in the absence of genetic tumor cell modification (i.e., CD80 expression). 21 Allostimulation was not considered a problem for the activation of melanoma-specific T cells. CD80 transfection into melanomas improved their ability to induce allogeneic HLA-A2-matched T-cell responses directed against the autologous tumor. 23 Kaufmann et al reported the generation of human papillomavirus 16 E7-specific T lymphocytes from healthy donors following stimulation with CD80-transfected allogeneic HLA-A2.1-matched cervical carcinoma cells. 24 Nevertheless, this response was demonstrable only after diluting the T cells in low density cultures, probably due to the low frequency of human papillomavirus-specific T cells in healthy individuals.
Our data represent the first quantitative comparison of tumor cells equipped with costimulatory molecules and professional APCs in inducing Ag-specific T cells. CD80 expression, together with IFN-␥/TNF-␣ treatment, rendered KS breast carcinoma cells almost as immunogenic as a physiologic mixture of professional APCs, including B lymphocytes, monocytes, and dendritic cells obtained from PBMC preparations.
With the intention of further supporting the induction of Ag-specific immune responses, combinations of CD80-expressing tumor variants and cytokines were analyzed. The combination of CD80 expression with either IL-4, IL-7, or IL-12 secretion by tumor cells resulted in improved antitumor immune responses when tested in syngeneic murine tumor models. [25] [26] [27] [28] All of the cytokines used enhanced T-cell expansion after induction with CD80-transfected KS breast carcinoma cells. IL-7, but also IL-4, appeared to be good at supporting Ag-specific T-cell stimulation, whereas IL-12 primarily augmented NK activity. The ability of IL-4 to support Ag specificity has been shown previously and may be due to a suppression of NK cell activation. In contrast, IL-12 is known to support the activation of both the Th1 subset and NK cells. NK-like activity following IL-12 administration was particularly obvious in an increased activity against K562 and a higher frequency of T cells secreting IFN-␥ in response to stimulation with tumor cells in the absence of MP Ag. The influence of gene-modified allogeneic tumor vaccines expressing combinations of CD80 and IL-4 or IL-7 on tumor Ag presentation was reported recently by Cayeux et al. 27 Whereas direct Ag presentation by the tumor itself was augmented by CD80 alone, it was shown in a series of experiments that IL-4 and IL-7 augmented the indirect presentation of the model tumor . 27 The combination of costimulatory molecules and cytokines in a tumor cell vaccine may be advantageous for the induction of a tumor-specific immune response. However, it should be noted that we demonstrated recently that IL-12 only cooperates with CD86-mediated activation in rechallenge stimulations, but represses the proliferative response of naive cells. 29 Therefore, it is necessary to analyze the possible divergent effects of cytokines together with genetic tumor cell modifications prior to the assessment in clinical studies.
We have shown in vitro that, with regard to the Ag presented by shared HLA molecules, CD80-expressing KS breast carcinoma cells act like APCs and directly activate specific CTLs. As previously discussed, the presentation of additional shared tumor Ags could occur in vivo by the host's own APCs as a result of indirect Ag presentation (cross-priming). The advantage of such an approach is that several T-cell clones with different specificities for putative tumor Ag can be induced. Thus far, the limited knowledge of tumor Ags has restricted the application of peptide-based cancer vaccines mainly to melanomas, for which several Ag have been thoroughly characterized. However, the success of this vaccination strategy seemed strictly dependent upon the mode of administration and formulation. Depending upon the tumor type, different adjuvants such as polycations are necessary to stabilize the peptide and support the internalization by APCs. Remarkably, it was reported that viral immunogenic peptides in combination with incomplete Freund's adjuvant can induce tolerance rather than protection, and that vaccination with a single peptide Ag may lead to the down-regulation of the corresponding Ag followed by immune escape of the tumor. 30 , 31 Schmidt et al 32 compared peptide-based cancer vaccines with autologous cellular immunization protocols in a murine melanoma system. Even if applied in an optimized formulation, a combination of immunodominant melanoma Ag was less potent in inducing systemic antitumor immunity than cellular vaccines consisting of irradiated IL-2-or GM-CSF-secreting tumor variants. 32 The efficiency of peptide vaccines may be improved as soon as more immunodominant peptides have been identified and their introduction in the host Ag-presenting system is optimized.
Our study clearly demonstrated the advantage of ELISPOT technology for the quantitative analysis of T-lymphocyte reactions. Using ELISPOT experiments as a means of counting the number of reactive T cells represents a method of evaluation for the capacity of an APC to activate and amplify specific precursor cells. We found previously that the frequency of IFN-␥-releasing T cells correlates with the cytolytic activity of a T-cell population. 33 However, due to analysis at the single-cell level, ELISPOT experiments are ϳ100 times more sensitive than cytotoxicity experiments with pooled cells at detecting specific T lymphocytes. We believe that this experimental setting may also be suitable for analysis of the T-cell responses induced in vivo by HLA-A2.1-matched, gene-modified breast carcinoma cells, expressing known tumor Ag (i.e., Her2/neu) and viral model Ag, to validate the outcome of a vaccination.
